C4 Therapeutics, Inc. financial data

Symbol
CCCC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 120, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 576 % -12.3%
Debt-to-equity 53.9 % +6.27%
Return On Equity -44.6 % +12%
Return On Assets -29 % +13.8%
Operating Margin -405 % +55.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 69.3M shares +41%
Common Stock, Shares, Outstanding 68.8M shares +40.3%
Entity Public Float 130M USD -35.6%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 68.8M shares +40.2%
Weighted Average Number of Shares Outstanding, Diluted 68.8M shares +40.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 29.4M USD +83.3%
Research and Development Expense 105M USD -12%
General and Administrative Expense 40.8M USD -1.24%
Operating Income (Loss) -119M USD +17.8%
Nonoperating Income (Expense) 12.3M USD +160%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -107M USD +50.7%
Income Tax Expense (Benefit) 1.28M USD
Net Income (Loss) Attributable to Parent -108M USD +22.9%
Earnings Per Share, Basic -1.9 USD/shares +33.3%
Earnings Per Share, Diluted -1.9 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 73.1M USD +62.9%
Marketable Securities, Current 264M USD +10.4%
Cash, Cash Equivalents, and Short-term Investments 296M USD +3.14%
Accounts Receivable, after Allowance for Credit Loss, Current 1.17M USD +13.5%
Assets, Current 276M USD +0.6%
Property, Plant and Equipment, Net 6.57M USD -13.2%
Operating Lease, Right-of-Use Asset 60.8M USD -9.37%
Other Assets, Noncurrent 2.62M USD -20.4%
Assets 381M USD +1.62%
Accounts Payable, Current 913K USD -59.4%
Contract with Customer, Liability, Current 36.6M USD +162%
Liabilities, Current 54.2M USD +12.4%
Contract with Customer, Liability, Noncurrent 16.9M USD -31.4%
Operating Lease, Liability, Noncurrent 62.9M USD -8.03%
Liabilities 134M USD -5.14%
Accumulated Other Comprehensive Income (Loss), Net of Tax -440K USD +75.2%
Retained Earnings (Accumulated Deficit) -574M USD -23.1%
Stockholders' Equity Attributable to Parent 247M USD +5.71%
Liabilities and Equity 381M USD +1.62%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.1M USD +45.3%
Net Cash Provided by (Used in) Financing Activities 34.6M USD
Net Cash Provided by (Used in) Investing Activities -53.4M USD -200%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 68.8M shares +40.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -36.9M USD -287%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.6M USD +59%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 146M USD +32.2%
Deferred Tax Assets, Gross 166M USD +25.9%
Operating Lease, Liability 71M USD -6.2%
Depreciation 1.32M USD -32%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -107M USD +22.3%
Lessee, Operating Lease, Liability, to be Paid 89M USD -8.78%
Property, Plant and Equipment, Gross 15.1M USD -1.86%
Operating Lease, Liability, Current 5.49M USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.09M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.83M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.1M USD -17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.37M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 61M USD +12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.65M USD +2.99%
Operating Lease, Payments 2.18M USD +3.02%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 27.2M USD +6.05%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%